2023
P3BEP (ANZUP 1302): An international randomized phase 3 trial of accelerated versus standard BEP chemotherapy for male and female adults and children with intermediate- and poor-risk metastatic germ cell tumours (GCTs).
Zebic D, Stockler M, Martin A, Pashankar F, Tran B, Mazhar D, Huddart R, Wheater M, Walpole E, Dunwoodie E, Feldman D, Birtle A, Stevanovic A, Wyld D, Hanning F, Grimison P, Group A. P3BEP (ANZUP 1302): An international randomized phase 3 trial of accelerated versus standard BEP chemotherapy for male and female adults and children with intermediate- and poor-risk metastatic germ cell tumours (GCTs). Journal Of Clinical Oncology 2023, 41: tps431-tps431. DOI: 10.1200/jco.2023.41.6_suppl.tps431.Peer-Reviewed Original ResearchPoor-risk metastatic germ cell tumoursMetastatic germ cell tumorsGerm cell tumorsPhase 3 trialStandard BEPComplete responseStage ITwo-sided type IRandomized phase 3 trialCisplatin 20mg/Standard BEP chemotherapyBaseline blood samplesProgression-free survivalTrial of chemotherapyImproved cure ratesD1-5Post-chemotherapy treatmentTranslational substudyBEP chemotherapyLine chemotherapyOpen labelPrimary endpointStandard regimensFree survivalCR rate
2021
P3BEP (ANZUP 1302): An international randomized phase III trial of accelerated versus standard BEP chemotherapy for male and female adults and children with intermediate and poor-risk metastatic germ cell tumors (GCTs).
Subramaniam S, Toner G, Stockler M, Martin A, Pashankar F, Tran B, Jeffery M, Mazhar D, Huddart R, Walpole E, Stevanovic A, Wyld D, Hanning F, Wheater M, Balagtas J, Troon S, Birtle A, White J, Grimison P. P3BEP (ANZUP 1302): An international randomized phase III trial of accelerated versus standard BEP chemotherapy for male and female adults and children with intermediate and poor-risk metastatic germ cell tumors (GCTs). Journal Of Clinical Oncology 2021, 39: tps390-tps390. DOI: 10.1200/jco.2021.39.6_suppl.tps390.Peer-Reviewed Original ResearchMetastatic germ cell tumorsPoor-risk metastatic germ cell tumoursGerm cell tumorsStandard BEPComplete responseStage IInternational randomized phase III trialRandomized phase III trialStandard first-line chemotherapyCisplatin 20mg/Standard BEP chemotherapyBaseline blood samplesFirst-line chemotherapyPhase III trialsProgression-free survivalTrial of chemotherapyD1-5Post-chemotherapy treatmentClinical trial informationTranslational substudyBEP chemotherapyOpen labelPrimary endpointStandard regimensFree survival
2020
P3BEP (ANZUP 1302): An international randomized phase III trial of accelerated versus standard BEP chemotherapy for adult and pediatric male and female patients with intermediate and poor-risk metastatic germ cell tumors (GCTs).
Subramaniam S, Toner G, Stockler M, Martin A, Pashankar F, Frazier A, Mazhar D, Ford K, Walpole E, Stevanovic A, Wyld D, Troon S, Hanning F, Birtle A, Wheater M, Huddart R, White J, Spunt S, Grimison P. P3BEP (ANZUP 1302): An international randomized phase III trial of accelerated versus standard BEP chemotherapy for adult and pediatric male and female patients with intermediate and poor-risk metastatic germ cell tumors (GCTs). Journal Of Clinical Oncology 2020, 38: tps425-tps425. DOI: 10.1200/jco.2020.38.6_suppl.tps425.Peer-Reviewed Original ResearchMetastatic germ cell tumorsGerm cell tumorsProgression-free survivalPoor-risk metastatic germ cell tumoursStandard BEPLine chemotherapyInternational randomized phase III trialExtracranial germ cell tumorsRandomized phase III trialCisplatin 20mg/Standard BEP chemotherapyFavorable response ratePhase 3 trialPhase III trialsD1-5Age group malesArchival tumor tissueFormal interim analysisShorter cycle lengthsTranslational substudyBEP chemotherapyOpen labelPrimary endpointStandard regimenBaseline blood
2018
P3BEP (ANZUP 1302): An international randomized phase 3 trial of accelerated versus standard BEP chemotherapy for adult and paediatric male and female patients with intermediate and poor-risk metastatic germ cell tumors (GCTs).
Nayar N, Lawrence N, Stockler M, Martin A, Yip S, Wong N, Yeung A, Friedlander M, Mazhar D, Pashankar F, Quinn D, McDermott R, Walker R, Winstanley M, Hanning F, Weickhardt A, Stevanovic A, Davis I, Toner G, Grimison P. P3BEP (ANZUP 1302): An international randomized phase 3 trial of accelerated versus standard BEP chemotherapy for adult and paediatric male and female patients with intermediate and poor-risk metastatic germ cell tumors (GCTs). Journal Of Clinical Oncology 2018, 36: tps574-tps574. DOI: 10.1200/jco.2018.36.6_suppl.tps574.Peer-Reviewed Original ResearchMetastatic germ cell tumorsGerm cell tumorsProgression-free survivalPoor-risk metastatic germ cell tumoursPhase 3 trialResponse rateLine chemotherapyStandard BEPExtracranial germ cell tumorsRandomized phase 3 trialCisplatin 20mg/Complete response rateStandard BEP chemotherapyAge group malesArchival tumor tissuePEG-G-CSFShorter cycle lengthsTranslational substudyBEP chemotherapyOpen labelPrimary endpointStandard regimenBaseline bloodFree survivalWeekly doses